Joe Gabler Appointed Chief Growth Office at Paytient

Paytient, the leading provider of health plan affordability solutions, announces today the addition of Joe Gabler as Chief Growth Officer. Joe Gabler is a senior executive and healthcare consumer payments pioneer with nearly 20 years of experience building companies around winning cultures. Joe will join Paytient to drive growth and expansion as the company continues to partner with leading employers, payers, and PBMs.

Serving over 5,000 enterprise partners with nearly 25 million lives moving into 2025, Paytient welcomes Joe to scale its partnerships with mid-market employers, large commercial groups, leading payers, and Medicare plan sponsors to make healthcare more easily accessible for millions more Americans in the coming years.

“The Medicare Prescription Payment Plan in 2025 means that smoothing out-of-pocket costs over time is becoming a standard of care for healthcare in the United States. Paytient is well positioned to serve as the leading platform giving Americans a better ability to access and afford care,” said Brian Whorley, Founder and CEO of Paytient. “As we prepare for the growth this will bring, Joe’s proven ability to scale teams and operations with winning cultures is a fantastic and critical addition to our leadership team.

Joe Gabler comments:

“Paytient is improving healthcare with a strategy that puts choice and affordability in the hands of members, knowing they need to be at the heart of real change. I’ve seen what can happen when people are empowered to care for their whole health, which is increasingly out of reach these days. I’m incredibly excited to join the amazing team at Paytient and passionately help expand the reach of this mission.”
Joe Gabler spent the first 13 years of his career helping SPS Commerce (SPSC) grow from a small business to a hugely successful IPO and multi-billion dollar market value. There he held multiple operations, strategy, and growth management positions. The next 6 years saw him reinventing the healthcare benefits landscape, leveraging innovative consumer payments strategies at Solutran, now acquired by Optum. They built a market-leading payment network serving over half the Medicare Advantage market and processing billions of dollars yearly in consumer benefit payments. Paytient is excited to welcome Joe onto its executive leadership team and leverage his expertise to pursue new growth opportunities.
SourcePaytient

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”